News
- Author:
- Andrew D. Bowser
Publish date: October 2, 2018
NEW YORK – The NCCN has updated its practice guidelines to include the newly approved moxetumomab pasudotox injec...
News
- Author:
- Andrew D. Bowser
Publish date: October 2, 2018
NEW YORK – So far, BCMA-specific CAR T-cell therapies, BiTEs, and a BCMA antibody–drug conjugate show the greates...
News
- Author:
- Andrew D. Bowser
Publish date: October 2, 2018
A melanoma patient receiving pembrolizumab was diagnosed with antiphospholipid syndrome that resolved following discontinuation of that treatment.<...
News
- Author:
- Andrew D. Bowser
Publish date: October 1, 2018
NEW YORK – Physicians are watching data on venetoclax, which has the potential to treat a subset of patients who can’t tolerate intensive therapy.<...
News
- Author:
- Andrew D. Bowser
Publish date: October 1, 2018
Dr. James P. Allison and Dr. Tasuku Honjo share the Nobel Prize for their work on preventing brakes on T cells, which led to the development of che...
News
- Author:
- Andrew D. Bowser
Publish date: October 1, 2018
New York—Three novel treatment strategies that target B-cell maturation antigen (BCMA) are showing promise in recent multiple myeloma (MM) clinical tr...
News
- Author:
- Andrew D. Bowser
Publish date: September 29, 2018
While low-risk people don’t benefit, patients who are at mid to high cardiovascular risk clearly might.
Article
- Author:
- Andrew D. Bowser
Publish date: September 28, 2018
These are the first-ever evidence-based, consensus treatment guidelines based on symptom severity.
News
- Author:
- Andrew D. Bowser
Publish date: September 28, 2018
PHOENIX – Despite ASCO recommendations, many patients with early-stage breast cancers at low metastasis risk have undergone imaging tests for stagi...
News
- Author:
- Andrew D. Bowser
Publish date: September 27, 2018
The infliximab-dyyb biosimilar was only moderately less expensive than the originator infliximab product Remicade in the United States in 2017 unde...
News
- Author:
- Andrew D. Bowser
Publish date: September 26, 2018
Out of 753 cellular therapy trials listed at ClinicalTrials.gov as of March 30, 2018, 404 were CAR T therapy studies.
News
- Author:
- Andrew D. Bowser
Publish date: September 25, 2018
NEW YORK – Dr. John Allan of Cornell University said there’s enough evidence to favor early use of novel agents o...
News
- Author:
- Andrew D. Bowser
Publish date: September 25, 2018
NEW YORK – Early trials point to potential for CD30-specific CAR T-cell therapy.
News
- Author:
- Andrew D. Bowser
Publish date: September 25, 2018
The findings lend “further weight to the clinical guideline recommendation of CBT as the treatment of choice for insomnia.”
News
- Author:
- Andrew D. Bowser
Publish date: September 24, 2018
Patients who survive acute lymphoblastic leukemia still may face cognitive impairment later in life because of sepsis during treatment.
